EV-302 results ‘a leap forward’ for advanced urothelial carcinoma
Phase 3 trial findings demonstrate a significant improvement in overall survival for patients with treatment-naïve, advanced urothelial carcinoma who receive a combination of enfortumab vedotin and pembrolizumab compared with chemotherapy.
